CHUGAI PHARMACEUTICAL CO., LTD.
Gene therapy for ALS: A review: Molecular Therapy
Mechanism of Action | ZOLGENSMA® (onasemnogene abeparvovec-xioi)
Novartis' gene therapy Zolgensma gets Japan approval for neuromuscular disorder | S&P Global Market Intelligence
CHUGAI PHARMACEUTICAL CO., LTD.
How It Works | ZOLGENSMA® (onasemnogene abeparvovec-xioi)
The approved gene therapy drugs worldwide: from 1998 to 2019 - ScienceDirect
Disease Modifying Therapies for Children with Spinal Atrophy | DDDT
Gene therapy successes point to better therapies | PNAS
Mechanism of Action | ZOLGENSMA® (onasemnogene abeparvovec-xioi)
Advances and limitations for the treatment of spinal muscular atrophy | BMC Pediatrics | Full Text
Zolgensma for the Treatment of Spinal Muscular Atrophy, Novartis
Zolgensma® (onasemnogene abeparvovec) Mechanism of Action in Spinal Muscular Atrophy - YouTube
Challenges of gene delivery to the central nervous system and the growing use of biomaterial vectors - ScienceDirect
Expert recommendations and clinical considerations in the use of onasemnogene abeparvovec gene therapy for spinal muscular atrophy - Kichula - 2021 - Muscle & Nerve - Wiley Online Library
Engineering adeno-associated virus vectors for gene therapy | Nature Reviews Genetics
Gene Therapy for Spinal Muscular Atrophy: An Emerging Treatment Option for a Devastating Disease
Gene Therapy for Spinal Muscular Atrophy: An Emerging Treatment Option for a Devastating Disease
Comparative evaluation of AAV gene therapy, antisense therapy and small molecules therapy for treatment of SMA for efficacy and
Spinal Muscular Atrophy (SMA)
Bridging the Gap: Gene Therapy in a Patient With Spinal Muscular Atrophy Type 1 | Neurology
Mechanisms of action of main molecular therapeutic strategies that are... | Download Scientific Diagram
What Is SMA? | ZOLGENSMA® (onasemnogene abeparvovec-xioi)
Therapy development for spinal muscular atrophy: perspectives for muscular dystrophies and neurodegenerative disorders | Neurological Research and Practice | Full Text
SMA Gene Therapy is a Bargain - Even With a Price Tag of US $2.125 Million - BIO 501
